Regorafenib
(REH-goh-RA-feh-nib) This page contains brief information about regorafenib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Stivarga |
| | ||
| | ||
| FDA Approved: | | Yes |
Regorafenib is approved to treat:
- Colorectal cancer that has metastasized (spread to other parts of the body). It is used in patients who have not gotten better with other treatments.
Regorafenib is also being studied in the treatment of other types of cancer.
More About RegorafenibDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Targeted Cancer Therapies - Information about the use of this drug to treat cancer.
Research ResultsExperimental Drug Improves Survival in Previously Treated Metastatic Colorectal Cancer - Information about the use of this drug to treat cancer.
Dana-Farber Researchers Find New Targeted Therapy Effective in Patients With Drug-Resistant Metastatic Gastrointestinal Stromal Tumor - Information from the NCI Press Office about this drug.
Clinical Trials Accepting PatientsFind Clinical Trials for Regorafenib - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top
